Sanara Medtech (SMTI) Stock Price
Sanara Medtech Price
Revenue has compounded at 39.3% per year over the past 19 years to 103.12 M USD. Sanara Medtech's net margin stands at -36.4%, down from -32.8% several years earlier. Analysts set a median price target of 35.00 USD, implying 0.5% below the current price. Of 8 analysts, 0 rate the stock a buy — an overall Hold consensus.
Sanara Medtech stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Sanara Medtech business model & stock analysis
Frequently asked questions about Sanara Medtech
The business model of Sanara Medtech Inc focuses on developing and commercializing innovative biotechnology and medical device products. The company aims to provide advanced wound care solutions to cater to the growing needs of patients worldwide. Sanara Medtech Inc leverages its expertise in wound healing and tissue regeneration to develop cutting-edge products that enhance patient outcomes. By offering a diverse portfolio of advanced products, the company aims to address the unmet needs of healthcare professionals and improve the quality of life for patients. Sanara Medtech Inc continually strives to expand its market presence and deliver innovative solutions for wound healing and tissue repair.
Sanara Medtech Inc is primarily active in the medical technology industry.
The main competitors of Sanara Medtech Inc in the market include companies such as Acelity, Mölnlycke Health Care, and Smith & Nephew.
Sanara Medtech Inc, formerly known as Wound Management Technologies, is a Texas-based medical technology company. It specializes in developing and commercializing advanced wound care products. Established in 2014, Sanara Medtech focuses on delivering innovative solutions to address acute and chronic wounds. Their products include a range of advanced wound dressings, collagen-based dressings, and therapeutic lotions designed to promote healing and improve patient outcomes. With a dedicated team of experts and strong research and development capabilities, Sanara Medtech is committed to providing effective and reliable wound care solutions to patients and healthcare providers worldwide.
Sanara Medtech Inc has achieved several significant milestones. The company successfully developed and commercialized its flagship product, the BIAKŌS® Antimicrobial Barrier Film, which provides advanced wound care solutions. Sanara Medtech Inc also received FDA 510(k) clearance for its BIAKŌS® Wound Gel, expanding its product portfolio. Additionally, the company formed strategic partnerships with healthcare providers and established distribution agreements to enhance market reach. Sanara Medtech Inc's dedication to innovation, regulatory compliance, and customer satisfaction has solidified its position as a leader in the medical technology industry.
Sanara Medtech Inc is primarily present in the United States.
Sanara Medtech Inc is a reputable company known for its strong values and corporate philosophy. With a customer-centric approach, they prioritize innovation, excellence, and integrity in all their operations. Sanara Medtech Inc aims to provide cutting-edge medical technologies and solutions that improve patient outcomes and quality of life. Backed by a highly skilled team and state-of-the-art research, they strive to deliver superior healthcare products and services. By fostering partnerships and collaboration, Sanara Medtech Inc demonstrates a commitment to advancing medical advancements and driving positive change in the industry. Their dedication to promoting excellence and integrity sets them apart as a leader in the healthcare sector.
Analysts currently set an average price target of 35.00 USD for the Sanara Medtech stock (median: 35.00 USD), implying -0.5 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the Sanara Medtech stock: 0 recommend buying, 5 holding and 3 selling. For 2026, analysts expect Sanara Medtech to generate revenue of 116.83 M USD and earnings per share of 0.20 USD.
Converted at the current exchange rate, the Sanara Medtech share trades at 31.47 EUR (35.18 USD).
The Sanara Medtech share (SMTI) is listed on 1 stock exchanges, including: NASDAQ (SMTI).
Sanara Medtech Inc. is a leading company in the field of wound care and offers innovative products and solutions for wound healing. The company is headquartered in Dallas, Texas and was founded in 2014. It specializes in providing patients and medical professionals with new products and technologies with clinically proven results. Sanara Medtech operates in three main areas: wound healing, incontinence and hygiene products, and hernia care. In the field of wound healing, the company offers a range of products specifically designed to accelerate and improve wound healing. This is achieved through the use of innovative dressing systems that regulate moisture, temperature, and oxygen levels to achieve optimal healing outcomes. In the incontinence and hygiene products sector, Sanara Medtech provides bladder and bowel incontinence management. Special absorbent pads and underpads are provided that are suitable for both men and women. The company also offers effective and skin-friendly cleansing lotions and cleaning products. In the hernia care sector, the company offers various implants and meshes. These include both new developments and standard products used for the stabilization of abdominal wall hernias. The products are surgical instruments and medical devices manufactured to the highest quality standards to achieve the best possible benefit for patients. Sanara Medtech's business model is focused on the healthcare market and aims to provide the best customer service and products in the field of wound care and medical devices. To achieve this, the company works closely with medical professionals and patient organizations. Sanara Medtech is committed to continuously improving existing products and offering innovative solutions in wound care to provide the best possible benefit for patients. Innovation, quality, and customer service are the key elements of Sanara Medtech's business model. The company relies on effective organization and coordination of all business areas, from research and development to sales. Sanara Medtech also aims to ensure sustainable economic growth through appropriate measures. In summary, Sanara Medtech Inc. is a company operating in the fields of wound healing, incontinence and hygiene products, and hernia care. The company offers innovative products and solutions of the highest quality standard and is committed to achieving the best possible benefit for patients through continuous research and development. The close partnerships with medical professionals and patient organizations enable the company to develop innovative products and provide the best possible customer service.
The expected revenue of Sanara Medtech is 116.83 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Sanara Medtech is 1.70 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Sanara Medtech is currently 178.59. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sanara Medtech stock.
The price-to-sales ratio (P/S) of Sanara Medtech is currently 2.60. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sanara Medtech stock.
The Eulerpool Quality Score for Sanara Medtech is 5/10.
The ISIN of Sanara Medtech is US79957L1008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Sanara Medtech is SMTI. The ticker symbol is used to trade Sanara Medtech shares on the stock exchange.
Sanara Medtech stock
Sanara Medtech Peer Group
Sanara Medtech Ticker
Sanara Medtech FIGI
All fundamentals and in-depth analysis of Sanara Medtech
Our stock analysis for Sanara Medtech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sanara Medtech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.